Dendritic cells can be loaded with tumor antigens (e.g., tumor lysates, peptides, or RNA) and administered to the patient to stimulate both CD4+ and CD8+ T cell responses, which are critical for targeting and eliminating tumor cells. This evidence concerns the gene CD8A and neoplasm.